Rapid uniform ventricular tachycardia (VT) (> 270 beats/min) or ventricular flutter induced during electrophysiological studies is thought not to be clinically significant in patients without cardiac arrest or documented rapid VT. The purpose of the study was to follow up 73 patients with inducible ventricular flutter but without confirmed rapid spontaneous VT. A long follow up (mean 3-5 years) identified two groups of patients. The first group had an excellent outcome and was characterised by a normal 24 hour Holter monitoring. In the second group, however, the risk of cardiac mortality was high (35%) and spontaneous VT was < 270 beatslmin (26%) and was characterised by couplets or salvos of extrasystoles on Holter monitoring. In this group the history of syncope and decreased left ejection fraction increased the risk of mortality and VT. The presence of late potentials increased the risk of spontaneous VT. Electrophysiologically guided antiarrhythmic therapy reduced the risk of VT.
, range 36-77) of the 1 100 consecutive patients who had electrophysiological testing between January 1982 and December 1989 because of syncope, dilated cardiomyopathy, or myocardial infarction. For the purpose of this analysis, ventricular flutter was defined as having a cycle length of < 214 ms, being uniform on a 12 lead electrocardiogram, having an uniform QRS configuration and axis, having constant rate, and requiring overdrive pacing or defibrillation because of circulatory collapse and loss of consciousness. All patients with spontaneous cardiac arrest or documented rapid VT were excluded.
Sixty patients had coronary disease and a history of myocardial infarction. Five had idiopathic dilated cardiomyopathy, three had hypertrophic cardiomyopathy, two had mitral valve prolapse, and one had corrected tetralogy of Fallot. Two patients had no clinical evidence of heart disease.
The indication for ventricular stimulation was unexplained syncope or dizziness (27 patients) and systematic evaluation at least one month after myocardial infarction to identify patients at risk of ventricular tachycardia (n = 41) or for systematic evaluation of patients with idiopathic dilated cardiomyopathy (n = 5).
ELECTROPHYSIOLOGICAL STUDIES
After they had given their informed consent patients were studied in a fasting non-sedated state. Antiarrhythmic therapy was discontinued for at least four half lives before the study. Three quadripolar or bipolar electrode catheters were inserted percutaneously and were positioned in the heart under fluoroscopic guidance. The right ventricle was stimulated at the apex and infundibulum with a programmable stimulater (Explorer 2000 Ela) that delivered square wave electrical impulses of 1-8 ms duration with the amplitude set at twice the diastolic threshold.
Our protocol for ventricular premature electrocardiographic monitoring and serial programmed stimulation were used to determine the appropriate drug. If the class I drug was ineffective, amiodarone was tested and then a combination of P blocker and amiodarone. All 36 patients were treated with a combination of at least a class I drug and amiodarone. At electrophysiological testing protection was defined as the inability to provoke either a sustained VT or a non sustained VT (> 15 repetitive responses).8In 13 patients an effective drug regimen was identified. When the VT was still inducible the patient was treated with the drug that resulted in the disappearance of ventricular extrasystoles on the Holter monitoring, increased the tachycardia cycle length, and was tolerated best. failure. Another patient died of a non-cardiac cause. In 10 patients spontaneous relatively slow VT (< 250 beats/min) developed, in three this was complicated by ventricular fibrillation and caused death. VT developed one month to five years after the induction of ventricular flutter. One of these patients underwent cardiac transplatation and died.
Curves to show survival without cardiac death and without arrhythmic events (confirmed ventricular tachycardia or ventricular fibrillation or both) were calculated by the Kaplan-Meier product limit method (fig 1) . The actuarial probability of survival without cardiac death was 90 (3)% at one year, 85 (4)% at two years, and 74 (7)% at five years and the probability of freedom from arrhythmic events was 90 (3)% at one year and 88 (4)% at two years. 
